Entera Bio reports FY2024 net loss of $9.5M; cash $21M as of March 28, 2025

Entera Bio Ltd.

Net loss $9.5M ($0.25 per share) vs $8.9M ($0.31 per share) in FY2023.
Cash and equivalents $8.7M at Dec 31, 2024; $21M as of March 28, 2025 after new investments.
R&D expenses flat at $4.5M; G&A increased to $5.1M from $4.4M.
Entera and OPKO entered oral GLP-1/Glucagon license agreement; IND filing expected in 2025.
EB613 Phase 3 study planned pending FDA surrogate endpoint qualification; SABRE ruling awaited.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.